Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from JJ.

J&J Gets Support For $6.5B Baby Talc Settlement Amid Third Bankruptcy Bid: Report

The healthcare giant faces lawsuits from 61,000 claimants who allege that asbestos contamination in its talc products led to ovarian and other cancers.

International Business Times

South Africa drops probe of J&J after it agrees to lower price of TB drug and withdraws patent

Medical advocacy groups welcomed Johnson & Johnson’s decision not to enforce its patent on a critical tuberculosis medication, allowing its production at much lower prices, after South African authorities opened an investigation into the conglomerate

The Independent UK

J&J Faces New Class Action Suit Seeking Damages And Medical Monitoring For Cancer

Johnson & Johnson is facing another class action suit that seeks medical monitoring for cancer patients resulting from talc use.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Johnson & Johnson To Pay $700 Million As Talc Settlement

Johnson & Johnson has agreed to pay $700 million as settlement for charges filed by 42 states and Washington DC.

International Business Times

Johnson & Johnson to pay $700m to settle claims it misled consumers

Pharmaceutical giant’s payout settles allegations it misled consumers about safety of its talcum-based powder products.

Al Jazeera

Is there asbestos in your makeup? Why women with cancer are suing big beauty brands

As tens of thousands of lawsuits related to Johnson & Johnson’s Baby Powder flood US courts, many women are coming forward claiming that talc-based makeup gave them asbestos-related mesothelioma. Why is talc still present in almost all cosmetics?

The Guardian - UK

4 Top Dividend Kings to Earn Passive Income

Dividend Kings are companies with a long history of paying and increasing shareholder dividends, which signals strong financial health for investors looking to build a steady stream of passive income.

Barchart

Read news from The Economist, FT, and more,
with one subscription

20 Highest-Grossing Biotech Stocks: Giants Driving Innovation and Growth

Biotech stocks offers the potential for significant returns driven by breakthrough discoveries and advancements in healthcare, agriculture, and other industries.

International Business Times

The Guardian view on India-UK trade talks: don’t make it harder for the health service

Editorial: Britain is pushing for patent changes that could increase the cost of Indian generic drugs, diverting more of the NHS budget to big pharma

The Guardian - UK

2 Dividend Kings Yielding Around 3% to Grab Now

High yields aren't the only reason to buy shares of dividend-paying stocks. For investors seeking quality dividend stocks for passive income, here's a look at two companies with long track records of raising shareholder payouts.

Barchart

Rare clotting effect of early COVID shots finally explained — what could that mean for future vaccines?

Scientists have offered a new explanation for why COVID-19 vaccines that contained adenoviruses carried a rare-but-serious risk of blood clotting.

LiveScience

A CEO contender left Johnson & Johnson. Was she penalized for saying she wanted the job?

The exit of a Johnson & Johnson exec raises an age-old question about women's ambition.

Fortune

His dad worked on the factory floor at Johnson & Johnson. Now he’s the CFO

Joe Wolk, with J&J for over 25 years, talks about his path and the company's focus on innovation.

Fortune

South Africa, Colombia and others are fighting drugmakers over access to TB and HIV drugs

In a series of moves experts say signal a shift in how developing countries deal with pharmaceuticals, South Africa, Colombia and others have recently adopted a more combative approach towards drugmakers, pushing back on policies that deny treatment to millions of people with tuberculosis and HIV

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

2 Dividend Kings Warren Buffett Just Dumped

The legendary value investor slashed two consistent dividend-paying stocks from Berkshire Hathaway's portfolio in the latest quarter, according to regulatory filings.

Fortune

Generative AI is top of mind for all types of leaders, from Treasury Secretary Janet Yellen to J&J CEO Joaquin Duato

This week’s episode of Fortune‘s Leadership Next podcast features conversations from the Fortune CEO Initiative conference.

The Hindu

Johnson & Johnson not to enforce patents on TB drug

“The announcement will finally pave the way for unfettered access to affordable generic versions of bedaquiline for all people”

Fortune

This J&J exec sold Tylenol and Listerine. Now she runs its $27B medtech business

Ashley McEvoy pivoted from over-the-counter products to medical devices.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Big Pharma's Johnson & Johnson under investigation in South Africa over 'excessive' drug prices

U.S.-based pharmaceuticals company Johnson & Johnson is being investigated in South Africa for allegedly charging “excessive” prices for a key tuberculosis drug

The Independent UK

Johnson & Johnson is getting rid of its script logo after more than 130 years

Johnson & Johnson is signing off on a new logo, more than 130 years after creating the old one

Al Jazeera

South Africa ‘held to ransom’ by big pharma, overcharged for COVID vaccines

J&J, Pfizer charged South Africa between 15 and 33 percent more for COVID vaccine doses, contracts reveal.

The Guardian - UK

Cost of tuberculosis treatment halved in deal to permit generic versions

Johnson & Johnson’s year-long deal on life-saving drug bedaquiline is seen as critical move in campaign against disease

Barchart

Kenvue Joins S&P 500 on Friday: Time to Buy?

S&P Dow Jones Indices announced on Monday that Kenvue would join the S&P 500 on Friday. Tuesday’s volume and rising share price suggest that investors feel now is the time to buy its stock.

Fortune

Newest Fortune 500 member says large companies lose focus: 'You are little more remote from where the action is'

Kenvue, spun off from Johnson & Johnson in May, generated $15 billion in sales last year, enough to put it at rank 275 on 2022's Fortune 500 list.

The Hindu

Explained | Will generic supply of bedaquiline be accessible?

J&J's patent on bedaquiline expired, allowing generic manufacturers to supply the drug. J&J has filed secondary patents. Prices are expected to reduce 3-6x, but some countries are excluded from the deal, raising concerns.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.